Combining radiation therapies for advanced prostate cancer
Part of Cancer clinical trials.
This trial tests the combination of two radiation treatments for prostate cancer that has spread. The goal is to see if adding a targeted external beam can improve outcomes for patients who are already receiving a specific radioactive drug therapy (177Lu-PSMA).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be currently receiving 177Lu-PSMA treatment for metastatic prostate cancer.
- You should be able to carry out daily activities (ECOG score 0 or 1).
- You must have at least one area of cancer spread that can be treated with external beam radiation.
- You must be taking medication to protect your bones (like a bisphosphonate or denosumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a radioactive drug that seeks out prostate cancer cells (Lutetium-177) with an immunotherapy (pembrolizumab). It is for men whose castration-resistant prostate cancer has spread and is no longer controlled by current hormone treatments.
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
Hear when a new Prostate Cancer Metastatic Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.